• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Intersect ENT Inc.

    5/13/22 8:58:31 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care
    Get the next $XENT alert in real time by email
    POS AM 1 brhc10037408_s-3posam.htm S-3 POS AM
    Registration No. 333-238963

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549


     
    Post-Effective Amendment No. 1
    to
    FORM S-3 REGISTRATION STATEMENT NO. 333-238963
    UNDER THE SECURITIES ACT OF 1933


    Intersect ENT, Inc.
    (Exact name of registrant as specified in its charter)


     
    Delaware
     
    20-0280837
    (State or other jurisdiction of
    incorporation or organization)
     
    (I.R.S Employer
    Identification Number)

    1555 Adams Drive
    Menlo Park, California 94025
    (650) 641-2100
    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)


    Christopher Cleary
    Senior VP, Corporate Development
    Intersect ENT, Inc.
    1555 Adams Drive
    Menlo Park, California 94025
    (650) 641-2100

    (Name, address, including zip code, and telephone number, including area code, of agent for service)


    Copies to:
    Christopher D. Comeau
    Tara M. Fisher
    Ropes & Gray LLP
    Prudential Tower
    800 Boylston Street
    (617) 235-4824





    Approximate date of commencement of proposed sale to the public: Not applicable. Removal from registration of securities that were not sold pursuant to the above referenced registration statement.
     
    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box:  ☐
     
    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box:  ☐
     
    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐
     
    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐
     
    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.  ☐
     
    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.  ☐
     
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer
    ☐
    Accelerated filer
    ☒
           
    Non-accelerated filer
    ☐
    Smaller reporting company
    ☐
           
       
    Emerging growth company
    ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐


    EXPLANATORY NOTE
     
    DEREGISTRATION OF SECURITIES
     
    This Post-Effective Amendment No. 1 relates to the following Registration Statement filed by Intersect ENT, Inc., a Delaware corporation (the “Registrant” or the “Company”) on Form S-3 (the “Registration Statement”).
     

    •
    Registrationa Statement No. 333-238963, filed with the Securities and Exchange Commission on June 5, 2020, relating to the registration by the Company of 6,309,459 shares of common stock, par value $0.001 per share, of the Company (“Common Stock”).
     
    On May 13, 2022, pursuant to the Agreement and Plan of Merger, dated as of August 6, 2021 (the “Merger Agreement”), by and among the Company, Medtronic, Inc., a Minnesota corporation (“Parent”), and Project Kraken Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent (“Merger Sub”), Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
     
    As a result of the consummation of the transactions contemplated by the Merger Agreement, the Registrant has terminated all offerings of its securities pursuant to the Registration Statement. In accordance with an undertaking made by the Registrant in the Registration Statement to remove from registration by means of a post-effective amendment any securities which remain unsold at the termination of the offering, the Registrant hereby removes and withdraws from registration all securities of the Registrant registered pursuant to the Registration Statement that remain unsold or otherwise unissued as of the date hereof. The Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities, and the Registrant hereby terminates the effectiveness of the Registration Statement.


    SIGNATURES
     
    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Minneapolis, State of Minnesota on May 13, 2022.

     
    INTERSECT ENT, INC.
         
     
    By:
    /s/ Christopher Cleary
       
    Christopher Cleary
       
    Senior VP, Corporate Development
     
    Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign this Post-Effective Amendment No. 1 to the Registration Statement.



    Get the next $XENT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $XENT

    DatePrice TargetRatingAnalyst
    8/12/2021$28.25Outperform → Market Perform
    SVB Leerink
    8/10/2021Buy → Neutral
    BTIG
    8/9/2021$29.00 → $28.25Buy → Hold
    Canaccord Genuity
    8/9/2021$28.25Buy → Neutral
    Guggenheim
    6/24/2021$21.00 → $23.00Market Perform → Outperform
    SVB Leerink
    More analyst ratings

    $XENT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SINUVA issued to INTERSECT ENT INC

    Submission status for INTERSECT ENT INC's drug SINUVA (SUPPL-6) with active ingredient MOMETASONE FUROATE has changed to 'Approval' on 01/20/2023. Application Category: NDA, Application Number: 209310, Application Classification: Labeling

    1/23/23 11:02:41 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nalu Medical, Inc. Names Thomas West President and Chief Executive Officer

    Current President and CEO, Earl Fender, announces retirement CARLSBAD, Calif., July 14, 2022 /PRNewswire-PRWeb/ -- Nalu Medical, Inc. ("Nalu"), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced today that the Board of Directors has appointed Thomas "Tom" West as President and Chief Executive Officer. This leadership appointment is effective on August 8th and follows the decision by Earl Fender, Nalu's current CEO, to retire. Mr. Fender will remain as a consultant to the company for the next 12 months. Mr. West remarked, "I am very excited and honored to be leading Nalu. I believe Nalu's unique system and technology, including the

    7/14/22 12:05:00 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    Real-World Evidence Study Demonstrates Intersect ENT's PROPEL® Sinus Implant Reduces Healthcare Resource Utilization

    Data from first-of-its-kind study published in Current Medical Research and Opinion Patients receiving PROPEL® following endoscopic sinus surgery had statistically significant lower healthcare resource utilization over a postoperative period of 18 months, including all-cause otolaryngologist, ER/urgent care and outpatient visits, as well as sinus-related endoscopies Intersect ENT®, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today announced positive results of an observational, cohort study using real-world evidence (RWE) data from adult patients with chronic rhinosinusitis (CRS) with or without nasal polyps

    1/25/22 7:00:00 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    Orthofix Announces Appointment of Thomas A. West to Board of Directors

    Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that Thomas A. West has been named to the Company's Board of Directors and appointed to the Compensation and Talent Development Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005343/en/Thomas A. West named to Orthofix Board of Directors and appointed to the Compensation and Talent Development Committee. (Photo: Business Wire) Mr. West currently serves as the President, Chief Executive Officer and Director of Intersect ENT, Inc. (NASDAQ:XENT), a commercial stage drug-device company that pioneers

    12/14/21 7:00:00 AM ET
    $OFIX
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    SEC Filings

    View All

    SEC Form POSASR filed by Intersect ENT Inc.

    POSASR - Intersect ENT, Inc. (0001271214) (Filer)

    9/12/22 5:25:28 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    SEC Form RW WD filed by Intersect ENT Inc.

    RW WD - Intersect ENT, Inc. (0001271214) (Filer)

    9/12/22 1:10:59 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    SEC Form 15-12B filed by Intersect ENT Inc.

    15-12B - Intersect ENT, Inc. (0001271214) (Filer)

    5/23/22 6:08:00 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Hattangadi Neil A

    4 - Intersect ENT, Inc. (0001271214) (Issuer)

    5/16/22 6:58:08 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Meier Richard A closing all direct ownership in the company

    4 - Intersect ENT, Inc. (0001271214) (Issuer)

    5/16/22 6:43:33 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Fernandez Reyna M closing all direct ownership in the company

    4 - Intersect ENT, Inc. (0001271214) (Issuer)

    5/16/22 6:41:18 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Intersect ENT downgraded by SVB Leerink with a new price target

    SVB Leerink downgraded Intersect ENT from Outperform to Market Perform and set a new price target of $28.25

    8/12/21 4:49:01 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    Intersect ENT downgraded by BTIG

    BTIG downgraded Intersect ENT from Buy to Neutral

    8/10/21 5:09:28 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    Intersect ENT downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Intersect ENT from Buy to Hold and set a new price target of $28.25 from $29.00 previously

    8/9/21 10:22:16 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    Leadership Updates

    Live Leadership Updates

    View All

    Orthofix Announces Appointment of Thomas A. West to Board of Directors

    Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that Thomas A. West has been named to the Company's Board of Directors and appointed to the Compensation and Talent Development Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005343/en/Thomas A. West named to Orthofix Board of Directors and appointed to the Compensation and Talent Development Committee. (Photo: Business Wire) Mr. West currently serves as the President, Chief Executive Officer and Director of Intersect ENT, Inc. (NASDAQ:XENT), a commercial stage drug-device company that pioneers

    12/14/21 7:00:00 AM ET
    $OFIX
    $XENT
    Medical/Dental Instruments
    Health Care

    Intersect ENT Announces Appointment of New Vice President of Sales

    Mark L. Alley to serve as Vice President of Sales Intersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today announced the appointment of Mark L. Alley as Vice President of Sales, effective May 10, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210504005421/en/Mark L. Alley (Photo: Business Wire) Mr. Alley previously served as Chief Commercial Officer at medical device specialist Levita Magnetics Corp. He is a proven leader with over 20 years of commercial and sales success in companies ranging in size from start-ups to Fortune 500 compan

    5/4/21 7:00:00 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    Financials

    Live finance-specific insights

    View All

    Intersect ENT Reports Third Quarter 2021 Financial Results

    Intersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today reported financial results for the third quarter ended September 30, 2021. Total revenue was $24.4 million for the third quarter of 2021, up 7%, compared to $22.7 million for the same period of 2020. Gross profit for the third quarter of 2021 was $19.3 million and gross margin was 79.2%, compared to gross profit of $14.9 million and gross margin of 65.5% for the same period of 2020. Excluding the impact of intangible asset amortization, adjusted gross profit and adjusted gross margin for the third quarter of 2021 was $19.8 million and 81.2%, resp

    11/2/21 4:15:00 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    Intersect ENT Reports Second Quarter 2021 Financial Results

    Intersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today reported financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Overview Entered into a definitive agreement with Medtronic, in which Medtronic will acquire all outstanding shares of Intersect ENT. Revenue of $27.3 million in the second quarter of 2021, up 180%, compared to $9.8 million in the second quarter of 2020. Record quarterly SINUVA revenue of $2.7 million. Global Navigation and Balloon portfolio generated quarterly revenue of $1.6 million. Cash, cash equivalents, restricted cash, and short-term investm

    8/6/21 7:15:00 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    Intersect ENT to Report Second Quarter 2021 Financial Results on August 6

    Intersect ENT, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient care, today announced that it will release second quarter 2021 financial results on Friday, August 6, 2021. The Company expects to issue the release at approximately 7:00 a.m. ET and management will host a conference call at 8:30 a.m. ET. To access the conference call via the Internet, go to the "Investor Relations" page of the Company's website at www.intersectENT.com. To access the live conference call via phone, dial 844-850-0548 and ask to join the Intersect ENT call. International callers may access the live call by dialing 412-317-5205. Participants may

    7/23/21 8:00:00 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    $XENT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Intersect ENT Inc. (Amendment)

    SC 13G/A - Intersect ENT, Inc. (0001271214) (Subject)

    2/23/22 8:56:48 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Intersect ENT Inc. (Amendment)

    SC 13G/A - Intersect ENT, Inc. (0001271214) (Subject)

    2/17/22 11:40:20 AM ET
    $XENT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Intersect ENT Inc. (Amendment)

    SC 13G/A - Intersect ENT, Inc. (0001271214) (Subject)

    2/14/22 4:41:22 PM ET
    $XENT
    Medical/Dental Instruments
    Health Care